AXSM Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

186.72M

+57.22%

-0.920

-40.26%

188.33M

+55.05%

-0.548

-55.08%

219.53M

+46.31%

-0.142

-85.36%

Estimates Revision

The market is revising Upward the revenue expectations for Axsome Therapeutics, Inc. (AXSM) for FY2025, with the revenue forecasts being adjusted by 1.33% over the past three months. During the same period, the stock price has changed by 38.25%.

Revenue Estimates for FY2025

Revise Upward

+1.33%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+4.36%

In Past 3 Month

Stock Price

Go Up

+38.25%

In Past 3 Month

15 Analyst Rating

Wall Street analysts forecast AXSM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AXSM is 175.25 USD with a low forecast of 148.00 USD and a high forecast of 202.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

15 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

148.00

Averages

175.25

High

202.00

Current: 0.000

Low

148.00

Averages

175.25

High

202.00

Morgan Stanley

Overweight -> Equal Weight

downgrade

$196 -> $204

2026-01-08

New

Reason

Morgan Stanley

Price Target

$196 -> $204

2026-01-08

New

downgrade

Overweight -> Equal Weight

Reason

Morgan Stanley downgraded Axsome Therapeutics to Equal Weight from Overweight with a price target of $204, up from $196. Axsome announced on December 31 that the FDA accepted the AXS-05 sNDA for Alzheimer's Disease Agitation with Priority Review, immediately driving a sharp stock reaction, notes the analyst, who increased the firm's view of the probability of success for AXS05 in ADA to 85% from 75%. However, the post-event run-up has meaningfully reduced near-term upside from current levels, says the analyst, who views 2026 as "relatively catalyst-light" outside of the April-end PDUFA date for AXS-05 in ADA.

UBS

NULL -> Buy

upgrade

$163 -> $248

2026-01-06

New

Reason

UBS

Price Target

$163 -> $248

2026-01-06

New

upgrade

NULL -> Buy

Reason

UBS raised the firm's price target on Axsome Therapeutics to $248 from $163 and keeps a Buy rating on the shares. The Biotech sector enters 2026 on a cautiously optimistic note, the analyst tells investors in a research note. While capital absorption from secondary offerings is a concern, over $47B of pending capital from potential M&A could offset this, though sustained outperformance will likely require M&A activity to continue outpacing secondaries and IPOs, the firm says.

Needham

Ami Fadia

Buy

maintain

$169 -> $225

2026-01-05

New

Reason

Needham

Ami Fadia

Price Target

$169 -> $225

2026-01-05

New

maintain

Buy

Reason

Needham analyst Ami Fadia raised the firm's price target on Axsome Therapeutics to $225 from $169 and keeps a Buy rating on the shares. The firm sees traction in 2026 for the company, based on potential approval and launch of Auvelity in Alzheimer's disease agitation and pipeline development. Needham also expects continued strong performance of Auvelity in major depressive disorder.

H.C. Wainwright

Buy

maintain

$185 -> $200

2026-01-05

New

Reason

H.C. Wainwright

Price Target

$185 -> $200

2026-01-05

New

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Axsome Therapeutics to $200 from $185 and keeps a Buy rating on the shares after the AXS-05 regulatory application was accepted with priority review. The firm increased its market penetration assumptions for AXS-05 given the potential for regulatory approval and market entry during the first half of 2026.

Mizuho

Graig Suvannavejh

Outperform

maintain

$202 -> $217

2025-12-31

Reason

Mizuho

Graig Suvannavejh

Price Target

$202 -> $217

2025-12-31

maintain

Outperform

Reason

Mizuho analyst Graig Suvannavejh raised the firm's price target on Axsome Therapeutics to $217 from $202 and keeps an Outperform rating on the shares. The firm notes the company announced two pieces of positive regulatory news, namely the FDA acceptance of the sNDA for AXS-05 for treatment of Alzheimer's disease agitation/ADA - with priority review granted and a PDUFA date of April 30, 2026 assigned; and receipt of FDA minutes regarding the company's recent pre-NDA meeting for AXS-12 that ultimately are supportive of an NDA submission for that candidate for the treatment of narcolepsy. Given these favorable updates, Mizuho increases its probability of success assumptions for both assets.

Mizuho

Outperform

maintain

$200 -> $202

2025-11-06

Reason

Mizuho

Price Target

$200 -> $202

2025-11-06

maintain

Outperform

Reason

Mizuho raised the firm's price target on Axsome Therapeutics to $202 from $200 and keeps an Outperform rating on the shares. The company reported strong Q3 results with sales beats for both Auvelity and Sunosi, the analyst tells investors in a research note.

Valuation Metrics

The current forward P/E ratio for Axsome Therapeutics Inc (AXSM.O) is -122.77, compared to its 5-year average forward P/E of -23.39. For a more detailed relative valuation and DCF analysis to assess Axsome Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-23.39

Current PE

-122.77

Overvalued PE

-2.86

Undervalued PE

-43.91

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-18.94

Current EV/EBITDA

230.47

Overvalued EV/EBITDA

65.01

Undervalued EV/EBITDA

-102.90

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

1345.92

Current PS

10.38

Overvalued PS

7489.91

Undervalued PS

-4798.07

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

AXSM News & Events

Events Timeline

No data

News

7.5

01-08Fool

Axsome and Exelixis: New Investment Opportunities in Biotech

9.5

01-08NASDAQ.COM

Axsome and Exelixis Show Significant Revenue Growth in Biotech Sector

5.0

01-05Yahoo Finance

Axsome Therapeutics Director Mark E Saad Sells 37,577 Shares for $6 Each

People Also Watch

Frequently Asked Questions

What is Axsome Therapeutics Inc (AXSM) stock price today?

The current price of AXSM is 169.38 USD — it has increased 1.09 % in the last trading day.

What is Axsome Therapeutics Inc (AXSM)'s business?

Axsome Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for people living with central nervous system (CNS) conditions. The Company's commercial products include Auvelity, Sunosi and Symbravo. It is also advancing a diversified, late-stage pipeline of product candidates for serious neurological and psychiatric conditions, which include AXS-05, AXS-12, AXS-14 and AXS-17. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. Symbravo (meloxicam and rizatriptan, 20 mg/10mg tablets) is an oral, single-dose medicine approved for the acute treatment of migraine with or without aura in adults.

What is the price predicton of AXSM Stock?

What is Axsome Therapeutics Inc (AXSM)'s revenue for the last quarter?

Axsome Therapeutics Inc revenue for the last quarter amounts to 170.99M USD, increased 63.22 % YoY.

What is Axsome Therapeutics Inc (AXSM)'s earnings per share (EPS) for the last quarter?

Axsome Therapeutics Inc. EPS for the last quarter amounts to -0.94 USD, decreased -29.85 % YoY.

What changes have occurred in the market's expectations for Axsome Therapeutics Inc (AXSM)'s fundamentals?

How many employees does Axsome Therapeutics Inc (AXSM). have?

Axsome Therapeutics Inc (AXSM) has 683 emplpoyees as of January 10 2026.

What is Axsome Therapeutics Inc (AXSM) market cap?

Today AXSM has the market capitalization of 8.54B USD.